Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
Researchers anticipate more cases of cancer could arise in the coming years and are conducting regular blood tests to monitor the patients.Newly released data reveals that seven out of 67 children treated with Bluebird Bio Inc's (NASDAQ:BLUE) gene therapy for a severe neurological disorder in clinical trials have developed blood cancers.
最新發布的數據顯示，在臨床試驗中接受Bluebird Bio Inc（納斯達克：BLUE）基因療法治療嚴重神經系統疾病的67名兒童中，有7名患者患上了血液癌症。
This marks an increase of four cases since June 2022, when the emergence of three cancer cases led the FDA to convene an advisory panel before approving the therapy, now marketed as Skysona. The STAT News report noted that one child passed away due to complications from cancer treatment.
這標誌着自2022年6月以來新增四例病例，當時出現了三例癌症病例，導致FDA在批准該療法之前召開了顧問小組會議，現在該療法以Skysona的名義在市場上銷售。 STAt資訊報告指出，一名兒童因癌症治療併發症去世。
Also Read: Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year.
另請閱讀：基因療法公司bluebird bio進行重組，裁員25%，旨在於明年實現盈虧平衡。
Researchers anticipate more cases of cancer could arise in the coming years and are conducting regular blood tests to monitor the patients.
研究人員預計未來幾年可能會出現更多癌症病例，並正在進行定期血液檢測以監測患者情況。
In September 2022, the FDA approved Bluebird Bio's Skysona, aka eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD).
2022年9月，FDA批准了bluebird bio的Skysona，又名eli-cel，用於減緩4-17歲患有早期、活動性腦腺髓變性（CALD）的男孩神經功能障礙的進展。
When in December 2023, the FDA approved Bluebird Bio's Lyfgenia (lovotibeglogene autotemcel (lovo-cel)) cell-based gene therapy for sickle cell disease, a black box warning was included in the label for Lyfgenia as hematologic malignancy (blood cancer) occurred in patients treated with Lyfgenia.
2023年12月，FDA批准了bluebird bio的Lyfgenia（lovotibeglogene autotemcel（lovo-cel））基因治療，用於鐮狀細胞病，標籤中包含了黑框警告，因爲接受Lyfgenia治療的患者出現了血液惡性腫瘤（血癌）情況。
In April 2022, Bluebird Bio laid off about 30% of its workforce. The gene therapy-focused company is showing the exit to nearly one-third of its staff to extend its cash runway into the first half of 2023 and save $160 million over the next two years.
2022年4月，bluebird bio裁員約30%。這家以基因療法爲重點的公司正在辭退近三分之一的員工，以延長現金運營時間至2023年上半年，並在接下來的兩年內節省1.6億美元。
Bluebird plans to reduce its workforce across the second and third quarters of 2022, the company revealed in an SEC filing.
bluebird計劃在2022年第二和第三季度裁減員工，該公司在一份SEC文件中透露。
The biotech said it planned to spend less than $400 million in 2022.
生物技術公司表示，計劃在2022年花費不到4億美元。
Price Action: At the last check on Friday, BLUE stock was trading higher by 3.09% to $0.51 premarket.
股價走勢：在上週五最新數據顯示，bluebird bio股票盤前上漲3.09%，達到0.51美元。
- MercadoLibre Poised For 30% Upside As Gross Merchandise Value And Payment Volume Surge, Says Goldman Sachs.
- 高盛表示，mercadolibre有望上漲30%，商品總價值和支付成交量激增。
譯文內容由第三人軟體翻譯。
